drugset / Trial / NCT02231658

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

NCT02231658

Phase 1 Terminated 109 enrolled Profil Institute for Metabolic Research GmbH
RandomizedParallel-groupSingle-blindTreatment

Summary

The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.

Timeline

Start
2015-07-16
Primary completion
2018-07-23
Completion
2018-07-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg Subcutaneous
Subject Lixisenatide Peptide 20 ug Subcutaneous

Indications